Association of Cystatin C Level with All-cause Mortality in Patients with Liver Cirrhosis: A Meta-analysis-Reference-Cited by-同舟云学术

Association of Cystatin C Level with All-cause Mortality in Patients with Liver Cirrhosis: A Meta-analysis

Published:2024-08 Issue:25 Volume:31 Page:3977-3986
ISSN:0929-8673
Container-title:Current Medicinal Chemistry
language:en
Short-container-title:CMC

Author:

Wang Xiaoyan¹,Xu Wei²,Yao Lin²,Jie Yu²,Gao Zhenjun³,Fan Yu²

Affiliation:

1. Department of Gastroenterology, The Suqian Clinical College of Xuzhou Medical University, Suqian, Jiangsu, 223800, China

2. Institute of Molecular Biology & Translational Medicine, The Affiliated People’s Hospital, Jiangsu University, Zhenjiang, Jiangsu, 212002, China

3. Department of Digestive Disease, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, 201700, China

Abstract

Background and Objective:: Blood cystatin C level has been introduced as a promising biomarker to detect early kidney injury in cirrhotic patients. The purpose of this meta-analysis was to investigate the association of blood cystatin C level with allcause mortality in patients with liver cirrhosis. Methods:: PubMed, ScienceDirect, and Embase databases were searched from the inception to November 15, 2022. Observational studies evaluating the value of blood cystatin C level in predicting all-cause mortality in patients with ACS were selected. The pooled hazard risk (HR) with 95% confidence intervals (CI) was calculated using a random effect model meta-analysis. Results:: Twelve studies with 1983 cirrhotic patients were identified. The pooled adjusted HR of all-cause mortality was 3.59 (95% CI 2.39-5.39) for the high versus low group of cystatin C level. Stratified analysis by study design, characteristics of patients, geographical region, sample size, and length of follow-up further supported the predictive value elevated cystatin C level. Conclusion:: Elevated cystatin C level was an independent predictor of poor survival in patients with liver cirrhosis. Detection of blood cystatin C level may provide important prognostic information in cirrhotic patients.

Funder

Suqian Science and Technology Support Project Fund

Zhenjiang Key Research and Development Fund

Jiangsu 333 Talent Fund

Suqian Key Science and Technology R&D Plan

Publisher

Bentham Science Publishers Ltd.

Reference41 articles.

1. Fortea J.I.; Crespo J.; Puente Á.; Cirrhosis, a global and challenging disease. J Clin Med 2022,11(21),6512

2. Sepanlou S.G.; Safiri S.; Bisignano C.; Ikuta K.S.; Merat S.; Saberifiroozi M.; Poustchi H.; Tsoi D.; Colombara D.V.; Abdoli A.; Adedoyin R.A.; Afarideh M.; Agrawal S.; Ahmad S.; Ahmadian E.; Ahmadpour E.; Akinyemiju T.; Akunna C.J.; Alipour V.; Almasi-Hashiani A.; Almulhim A.M.; Al-Raddadi R.M.; Alvis-Guzman N.; Anber N.H.; Angus C.; Anoushiravani A.; Arabloo J.; Araya E.M.; Asmelash D.; Ataeinia B.; Ataro Z.; Atout M.M.W.; Ausloos F.; Awasthi A.; Badawi A.; Banach M.; Bejarano Ramirez D.F.; Bhagavathula A.S.; Bhala N.; Bhattacharyya K.; Biondi A.; Bolla S.R.; Boloor A.; Borzì A.M.; Butt Z.A.; Cámera L.L.A.A.; Campos-Nonato I.R.; Carvalho F.; Chu D-T.; Chung S-C.; Cortesi P.A.; Costa V.M.; Cowie B.C.; Daryani A.; de Courten B.; Demoz G.T.; Desai R.; Dharmaratne S.D.; Djalalinia S.; Do H.T.; Dorostkar F.; Drake T.M.; Dubey M.; Duncan B.B.; Effiong A.; Eftekhari A.; Elsharkawy A.; Etemadi A.; Farahmand M.; Farzadfar F.; Fernandes E.; Filip I.; Fischer F.; Gebremedhin K.B.B.; Geta B.; Gilani S.A.; Gill P.S.; Gutirrez R.A.; Haile M.T.; Haj-Mirzaian A.; Hamid S.S.; Hasankhani M.; Hasanzadeh A.; Hashemian M.; Hassen H.Y.; Hay S.I.; Hayat K.; Heidari B.; Henok A.; Hoang C.L.; Hostiuc M.; Hostiuc S.; Hsieh V.C.; Igumbor E.U.; Ilesanmi O.S.; Irvani S.S.N.; Jafari Balalami N.; James S.L.; Jeemon P.; Jha R.P.; Jonas J.B.; Jozwiak J.J.; Kabir A.; Kasaeian A.; Kassaye H.G.; Kefale A.T.; Khalilov R.; Khan M.A.; Khan E.A.; Khater A.; Kim Y.J.; Koyanagi A.; La Vecchia C.; Lim L-L.; Lopez A.D.; Lorkowski S.; Lotufo P.A.; Lozano R.; Magdy Abd El Razek M.; Mai H.T.; Manafi N.; Manafi A.; Mansournia M.A.; Mantovani L.G.; Mazzaglia G.; Mehta D.; Mendoza W.; Menezes R.G.; Mengesha M.M.; Meretoja T.J.; Mestrovic T.; Miazgowski B.; Miller T.R.; Mirrakhimov E.M.; Mithra P.; Moazen B.; Moghadaszadeh M.; Mohammadian-Hafshejani A.; Mohammed S.; Mokdad A.H.; Montero-Zamora P.A.; Moradi G.; Naimzada M.D.; Nayak V.; Negoi I.; Nguyen T.H.; Ofori-Asenso R.; Oh I-H.; Olagunju T.O.; Padubidri J.R.; Pakshir K.; Pana A.; Pathak M.; Pourshams A.; Rabiee N.; Radfar A.; Rafiei A.; Ramezanzadeh K.; Rana S.M.M.; Rawaf S.; Rawaf D.L.; Reiner R.C.; Roever L.; Room R.; Roshandel G.; Safari S.; Samy A.M.; Sanabria J.; Sartorius B.; Schmidt M.I.; Senthilkumaran S.; Shaikh M.A.; Sharif M.; Sharifi A.; Shigematsu M.; Singh J.A.; Soheili A.; Suleria H.A.R.; Teklehaimanot B.F.; Tesfay B.E.; Vacante M.; Vahedian-Azimi A.; Valdez P.R.; Vasankari T.J.; Vu G.T.; Waheed Y.; Weldegwergs K.G.; Werdecker A.; Westerman R.; Wondafrash D.Z.; Wondmieneh A.B.; Yeshitila Y.G.; Yonemoto N.; Yu C.; Zaidi Z.; Zarghi A.; Zelber-Sagi S.; Zewdie K.A.; Zhang Z-J.; Zhao X-J.; Naghavi M.; Malekzadeh R.; The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020,5(3),245-266

3. Juanola A.; Ma A.T.; Pose E.; Ginès P.; Novel biomarkers of AKI in cirrhosis. Semin Liver Dis 2022,42(4),489-500

4. Wong F.; O’Leary J.G.; Reddy K.R.; Garcia-Tsao G.; Fallon M.B.; Biggins S.W.; Subramanian R.M.; Thuluvath P.J.; Kamath P.S.; Patton H.; Maliakkal B.; Tandon P.; Vargas H.; Thacker L.; Bajaj J.S.; Acute kidney injury in cirrhosis: Baseline serum creatinine predicts patient outcomes. Am J Gastroenterol 2017,112(7),1103-1110

5. Wong F.; Acute kidney injury in liver cirrhosis: New definition and application. Clin Mol Hepatol 2016,22(4),415-422